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ABSTRACT
Mycoplasma is a well-recognised pathogen that colonises mucosal surfaces of humans and animals.
Mycoplasma pneumoniae infects the upper and lower respiratory tracts of children and adults, leading to a
wide range of respiratory and non-respiratory clinical conditions. M. pneumoniae infection is frequently
considered in the differential diagnosis of patients with respiratory illnesses, and is commonly managed
empirically with macrolides and fluoroquinolones. This contrasts with patients who present with non-
respiratory symptoms in the context of a recent or current unrecognised M. pneumoniae infection, for
whom this pathogen is rarely considered in the initial differential diagnosis. This review considers the
microbiological, epidemiological, pathogenic and clinical features of this frequent pathogen that need to
be considered in the differential diagnosis of respiratory and non-respiratory infections.
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INTRODUCTION
Recognition ofMycoplasma as a bacterial pathogen
took many years of intense clinical and research
work. The first published report concerning
Mycoplasma came from the French scientists
Nocard and Roux [1], who in 1898 described the
isolation, culture and infectivity of a microorgan-
ism associated with contagious bovine peri-pneu-
monia, later named Mycoplasma mycoides. No
reports concerning Mycoplasma in humans ap-
peared until 1942, when Eaton et al. [2] described
the isolation of a filterable agent recovered from
the sputum of patients with primary atypical
pneumonia. This agent, later named the Eaton
agent, was isolated from tissue cultures and
infected rodents, with the latter subsequently
developing a lung pathology similar to that
observed in humans. Finland et al. [3] demon-
strated that serum from patients with primary
atypical pneumonia contained cold agglutinins
capable of neutralising the Eaton agent. For many
years, the Eaton agent was believed to be a virus
particle rather than a bacterium [4]. The absence
of a cell wall, which gives Mycoplasma a pleomor-
phic phenotype and the ability to pass through
viral filters, as well as the difficulty of growing
this organism in cell-free culture conditions,
supported the hypothesis of the viral nature of
the Eaton agent for 20 years. Important develop-
ments during the 1960s included the isolation of
the Eaton agent from tissue culture cells and,
more importantly, from cell-free cultures, thus
demonstrating the bacterial nature of the Eaton
agent [5]. Induction of atypical pneumonia in
volunteers inoculated with purified isolates of the
Eaton agent provided proof that this bacterial
pathogen, later named Mycoplasma pneumoniae,
was an aetiological agent of atypical pneumonia
in humans [6].
M. pneumoniae is now known to be a frequent
respiratory pathogen in children as well as in
adults.M. pneumoniae infects the upper and lower
respiratory tracts, leading to upper respiratory
tract infection, bronchiolitis, tracheobronchitis,
bronchitis and community-acquired pneumonia.
It is also associated with asthma exacerbations
[7]. Interestingly, Mycoplasma respiratory tract
infections are associated with non-respiratory
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symptoms in many cases, manifesting in the skin,
mucosas, central nervous system (CNS) and other
tissues. Improved familiarity with clinical extra-
pulmonary manifestations ofM. pneumoniae infec-
tion may improve diagnosis and help to ensure
appropriate treatment.
MICROBIOLOGY
Mycoplasma belongs to the class Mollicutes, which
includes organisms lacking the genes necessary to
synthesise peptidoglycan cell walls. The class
Mollicutes comprises four orders, five families,
eight genera and 200 species [8,9]. Mollicutes are
related phylogenetically to Gram-positive bacte-
ria, based on 16S rRNA phylogenetic analysis.
Despite the genetic relatedness of Mycoplasma to
ancestral Gram-positive bacteria, the absence of a
cell wall prevents successful staining with Gram’s
strain. The Mycoplasma chromosome is circular
and c. 500 kb in size, making Mycoplasma one of
the smallest autonomously replicating living
organisms in nature [10].
The absence of a rigid cell wall makes Myco-
plasma pleomorphic and able to cross filters that
are otherwise permeable only to viruses. Myco-
plasma may have a spherical shape under hypo-
tonic conditions, and an irregular shape under
hypertonic conditions; dehydration kills Myco-
plasma [11,12]. All members of the Mycoplasma
genus require sterols for growth. These essential
components of the Mycoplasma membrane pro-
vide support to this osmotically fragile organism
[13].
Mycoplasma genomic DNA lacks almost all the
genes necessary for the biosynthesis of amino-
acids, fatty acids, co-factors and vitamins, and the
organism therefore depends on the host for a
supply of metabolic precursors [11]. This limited
biosynthetic potential means that mycoplasmas
are obligatory parasites with strict host and tissue
specificities [14]. Their host range includes plants,
insects, animals and humans [15]. In humans,
some colonising species behave as normal flora
(e.g., Mycoplasma salivarium, Mycoplasma orale),
while other species are clearly established patho-
gens (e.g., M. pneumoniae, Mycoplasma genitalium,
Mycoplasma hominis, Mycoplasma fermentans and,
possibly, Mycoplasma penetrans) [9,16]. M. pneumo-
niae may elaborate capsular material around the
cell membrane [17]. Little is known concerning
capsular expression, the genes necessary for its
biosynthesis, and its role in M. pneumoniae path-
ogenesis. Table 1 summarises the most important
biological characteristics of M. pneumoniae.
PATHOGENESIS
The Mollicutes are primarily mucosa-associated
organisms that reside in the host’s respiratory and
urogenital tracts in close association with epithe-
lial cells, yet are located extracellularly [18]. There
are several proposed mechanisms to explain
pathogenicity, including competition for precur-
sors, adherence to cells, fusion to cell membranes,
cell invasion and cytotoxicity [11,14].
Cyto-adherence and its importance in
pathogenesis
M. pneumoniae colonises the respiratory epithe-
lium by attaching to cilia [19]. Mycoplasma cyto-
adherence to the respiratory tract is the initial
event leading to colonisation, infection and lung
tissue damage [14]. P1, P30, P116 and HMW1–3
comprise a group of membrane proteins associ-
ated with Mycoplasma cyto-adherence [20–22],
some of which concentrate on a single attachment
tip organelle (Fig. 1) found at the surface of
Mycoplasma [23–25]. Alteration or the absence of
any of these proteins results in Mycoplasma
becoming avirulent [26,27].
Cell invasion and pathogenesis
Although M. pneumoniae is primarily an extracel-
lular pathogen that depends on close host–cell
contact for survival, in-vitro studies have shown
that it can penetrate cell membranes and invade
cells [28]. Another species, M. penetrans, is also
Table 1. Bacteriological features ofMycoplasma pneumoniae
Taxonomy Class Mollicute
Family Mycoplasmataceae
Order Mycoplasmatales
Genus Mycoplasma
Phylogenetics 16S rRNA sequence analysis indicates that
Mycoplasma split from Streptococcus
c. 605 million years previously
Genome 816 kb in size
Low G + C content
Limited metabolic and biosynthetic genes
In-vitro growth Requires complex media
Sterols essential for membrane stability
Low turbidity in culture
Features Pleomorphic because of the absence of a cell wall
Tip structure for attachment
Host Humans
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able to invade tissue culture cells, and is a
recognised pathogen that infects the genitouri-
nary tract of patients with AIDS [29,30]. In-vitro
evidence indicates that Mycoplasma can enter
tissue culture cells within 2 h, and can remain
intracellular for >7 days. Confocal microscopy
has identified Mycoplasma in perinuclear regions
and throughout the cell cytoplasm [31]. The
interaction between Mycoplasma and epithelial
cells triggers signals that induce recruitment
of cytoskeletal proteins, including tubulin and
a-actinin. Furthermore, it has been shown that
M. penetrans also binds the extracellular matrix
protein fibronectin, suggesting that signalling
mediated by integrin–fibronectin may induce
internalisation of Mycoplasma [32].
Cytotoxicity mediated by Mycoplasma
Mycoplasma internalisation into host cells is not
necessary for the initiation of local cytotoxic
events and clinical manifestations of disease.
Cytopathic changes can be related to the local
damage following cyto-adherence. Close contact
between Mycoplasma and host tissue allows local
disruption and cytotoxicity through the release of
enzymic and cytolytic metabolites directly on to
the cell [14]. Fusion of Mycoplasma membrane
to host-cell membrane may result in the release
of hydrolytic enzymes produced by Mycoplasma,
as well as the insertion of bacterial membrane
components into the host cell membrane.
Mycoplasma nucleases have been shown to induce
inter-nucleosomal DNA fragmentation in cul-
tured cells [33], and an ADP-ribosyltransferase
toxin with homology to pertussis toxin was
reported to induce vacuolisation of epithelial cells
[34]. Several epithelial cell proteins are targeted
by the vacuolising toxin, although none have so
far been identified.
Immune response and cytokine production
Mycoplasma activates the immune system by
inducing B- and T-lymphocyte proliferation,
secretion of major histocompatibility complex
class I and II proteins, and release of multiple
cytokines (e.g., interleukins, interferons, tumour
necrosis factor and colony-stimulating factors).
These effects may result in local or systemic
manifestations in the infected host. Cytokines are
important mediators of inflammation in respira-
tory and non-respiratory tissues, as demonstrated
by in-vivo and in-vitro studies (Table 2). Myco-
plasma spp. induce cytokines in tissue culture
cells, experimental animals and humans [19,35–
37]. Mycoplasma-mediated cytokine release in
infected children is associated with worsening
asthma symptoms [7]. Studies in mice indicate
that the T-helper 1 type of immune response
Fig. 1. Ultrastructural morphology of Mycoplasma pene-
trans. Transmission electron-microscopy image with neg-
ative staining showing elongated pleomorphic Mycoplasma
cells grown in cell-free culture. Arrows indicate attach-
ment tip organelle. Solid bar represents 200 nm (micro-
graph kindly provided by J. A. Giron, University of
Arizona, USA).
Table 2. Mycoplasma-mediated cytokine secretion and
organ-system effects
Cytokine Effect Reference
IL-1b Elevation associated with AHR [38]
Elevated in BALF and serum in MP [15]
IL-2 Elevated in BALF and serum in MP [15]
Suggested role in development of pulmonary lesions [43]
IL-4 Elevated production by Mast cells in vitro [79]
Involved in AHR in asthmatics [80]
Elevated in BALF and serum in MP [15]
IL-5 Elevation associated with AHR in children [7]
IL-6 Elevated production by Mast cells in vitro [79]
Elevation associated with AHR [38]
Elevation associated with CNS complications [63]
Elevated in BALF and serum in MP [38]
IL-8 Increase neutrophil influx to the alveolar spaces in MP [81]
Elevation associated with CNS complications [63]
Elevated in AHR patients [82]
IL-12 Elevation associated with AHR [38]
IL-18 Enhances NK cell cytotoxicity and T-lymphocyte activation [37]
Elevation associated with CNS complications [63]
Serum levels increased in acute MP [37]
IFN-d Elevation associated with AHR [38]
Increased macrophage and NK cell activity [16,42]
TNF-a Induced secretion by lung cells in vitro [15]
Elevation associated with AHR [38]
Elevated production by mast cells in vitro [79]
TGF-b1 Induced in airway epithelial cells [39]
RANTES Induced in airway epithelial cells [39]
RANTES, normal T-cell-expressed and secreted chemokine; MP, Mycoplasma
pneumonia; CNS, central nervous system; AHR, airway hyper-responsiveness;
BALF, bronchoalveolar lavage fluid; IL, interleukin; IFN, interferon; TNF, tumour
necrosis factor; TGF, transforming growth factor; NK, natural killer.
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induced by Mycoplasma is responsible for
increased airway obstruction and elevated airway
hyper-responsiveness [38]. The ciliated airway
epithelium is the primary site of Mycoplasma
infection, and is the principal source of a variety
of cytokines with a pro-inflammatory role [39].
Evidence suggests that cell surface lipoproteins
are the preferential target of the humoral immune
response [40].
Evasion and suppression of the immune
response
The major mechanisms implicated in the evasion
of the immune response by Mycoplasma include
molecular mimicry, survival within cells and
phenotypic plasticity. Some Mycoplasma spp.
may undergo changes in the lipoprotein reper-
toire expressed in the cell membrane as a way of
coping with a fluctuating environment and the
host immune response [40]. Furthermore,
M. pneumoniae may induce transient depression
of T-lymphocyte function and depletion of
CD4+ T-cells [41,42]. Induction of transient
anergy has also been described during the acute
phase of Mycoplasma infection [43]. Similarly, a
study in children acutely infected by M. pneumo-
niae reported a temporary suppression of the
immune system by mechanisms as yet unknown
[44].
EPIDEMIOLOGY
M. pneumoniae can be transmitted by aerosols
from person to person. Individuals with active
Mycoplasma infection carry organisms in the nose,
throat, trachea and sputum, with transmission
facilitated by coughing. The incubation period
varies from 1 to 3 weeks, although it is some-
times as short as 4 days [9,45]. During epidemics,
the presence of different subtypes may explain
the lack of a protective immune response against
subsequent infection [46]. Studies in outpatient
clinics in Seattle, WA, USA reported that
M. pneumoniae infection rates varied from 2% in
endemic years to 35% in epidemic periods.
Epidemics occurred every 4–7 years. A higher
proportion of children aged 5–9 years developed
pneumonia than did adolescents aged 15–
19 years [47]. Mycoplasma outbreaks tend to occur
in crowded environments or institutions such as
hospitals, military camps and college dormitories
[48,49]. Studies using PCR screening have indi-
cated that a possible carrier status may provide a
reservoir for these organisms. Although M. pneu-
moniae is not part of the normal flora, and its
presence is frequently associated with infection,
the microorganism may persist inside the host’s
respiratory tract for variable periods even after
the clinical manifestations have resolved [50].
Furthermore, M. pneumoniae infection tends to be
more severe among immunosuppressed indi-
viduals, including individuals with humoral
immune defects.
CLINICAL MANIFESTATIONS
M. pneumoniae infection most commonly affects
the upper and lower respiratory tracts. Upper
respiratory tract symptoms include sore throat,
hoarseness, fever, cough, headache, chills, coryza,
myalgias, earache and general malaise. Infections
of the lower respiratory tract generally manifest
with a cough, sometimes with dyspnoea, adenop-
athy, wheezing and, rarely, with respiratory
failure. Fulminant infections are uncommon.
Although M. pneumoniae infections are usually
mild, and many are asymptomatic, they are not
always self-limiting [9]. M. pneumoniae causes up
to 40% of cases of community-acquired pneumo-
nia, but M. pneumoniae respiratory tract infections
are also associated with a wide range of extra-
pulmonary manifestations, including neurologi-
cal, cardiac, dermatological, musculoskeletal,
haematological and gastrointestinal symptoms
[8,41,51,52] (Table 3).
The development of new techniques for the
detection of M. pneumoniae has revealed that this
organism can also be found in extra-pulmonary
tissues [16], with c. 25% of individuals infected
with M. pneumoniae experiencing extra-pulmo-
nary complications [8]. Extra-pulmonary manifes-
tations could occur before, after, during or in the
absence of respiratory symptoms. Extra-pulmo-
nary manifestations may occur not less than
3 days after the onset of respiratory disease, and
for 2–3 weeks after the respiratory disease has
resolved [53]. Whether infection itself or post-
infection inflammation is responsible for the
extra-pulmonary clinical manifestations is cur-
rently under investigation.
While M. pneumoniae most commonly infects
the respiratory tract, infections caused by Myco-
plasma spp. other than M. pneumoniae have been
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described in blood, brain tissue, cerebrospinal
fluid (CSF), skin, the urogenital tract, heart and
joints [9,16,29,54,55].
Skin and mucosal infections
Among patients with M. pneumoniae infection,
c. 25% may have dermatological manifestations,
making these some of the most common compli-
cations of this infection [43]. A wide range of skin
and mucosal manifestations has been described in
the literature (Table 3). There is a well-known
association between Mycoplasma and Stevens–
Johnson syndrome, erythema multiforme and
toxic epidermal necrolysis [56,57]. M. pneumoniae
is the most common infectious agent associated
with Stevens–Johnson syndrome [58,59].
Some cases of Stevens–Johnson syndrome
were reported to exclusively affect mucosal
membranes, leaving the skin intact [57,59]. It is
unclear at present whether this entity is a variant
of Stevens–Johnson syndrome or a new entity.
Patients with oral, as well as genitourinary,
mucosal lesions, generally manifest with fever
and generalised fatigue. Antimicrobial therapy
rapidly resolves the clinical condition.
The exact mechanism of skin and mucosal
disease is unknown, but immune complex-medi-
ated vascular injury, cell-mediated immune
response and cytotoxic injury to epithelial cells,
and autoimmune mechanisms have all been sug-
gested [57].WhileM. pneumoniaehas beendetected
directly in cutaneous lesions, there is no evidence
thatMycoplasma causes such lesions directly.
CNS manifestations
CNS manifestations are the most common extra-
pulmonary complications of M. pneumoniae infec-
tion. Encephalitis and meningoencephalitis are
most common, followed by polyradiculitis and
aseptic meningitis [41,51]. Frequently, a manifest
respiratory infection precedes the CNS
symptoms. The mean interval between the onset
of respiratory symptoms and CNS manifestations
is 9.6 days (range 2–14 days) [41,52]. M. pneumo-
niae infection should be routinely considered in
the differential diagnosis of patients with CNS
manifestations, especially if associated with
pneumonia [60]. Table 3 lists the neurological
conditions associated with Mycoplasma infection.
Among serologically confirmed M. pneumoniae
infections that require hospitalisation, c. 1–10%
are associated with neurological manifestations.
The overall incidence is <0.1%, although the
exact incidence of M. pneumoniae-associated
Table 3. Clinical manifestations caused by or associated
with Mycoplasma pneumoniae infection
Respiratory tract conditions directly related to M. pneumoniae infection
Tonsillitis
Rhinitis
Tracheobronchitis
Pharyngitis
Bronchiolitis
Croup
Bronchopneumonia
Atypical pneumonia
Asthma
Clinical conditions associated with M. pneumoniae infection by system
Neurological
Encephalitis
Meningoencephalitis
Cerebral ataxia
Aseptic meningitis
Transverse myelitis
Guillain–Barre´ syndrome
Polyradiculitis
Peripheral neuropathy
Optic neuritis
Cranial nerve palsies
Stroke
SIADH
Renal
Glomerulonephritis
Renal failure
Tubulointerstitial nephritis
IgA neuropathy
Dermatological
Erythematous maculo-papular and vesicular rashes
Generalised ulcerative stomatitis
Bullous exanthems
Stevens–Johnson syndrome
Erythematous maculo-papular rash
Vesicular rash
Erythema nodosum
Pityriasis rosea
Toxic epidermal necrolysis
Bullous erythema multiforme
Subcorneal pustular dermatosis
Ophthalmological
Conjunctivitis
Anterior uveitis
Retinitis
Retinal haemorrhages
Iritis
Optic disk swelling
Musculoskeletal
Arthralgias
Septic arthritis
Myalgias
Acute rhabdomyolysis
Haematological and cardiovascular
Haemolytic anaemia
Intravascular coagulation
Aplastic anaemia
Thrombotic thrombocytopenic purpura
Urticarial vasculitis
Leukocytolastic vasculitis
Henoch-Schoenlein purpura
Pericarditis
Myocarditis
Pericardial effusion
Raynaud phenomenon
Gastrointestinal
Diarrhoea
Cholestatic hepatitis
Pancreatitis
Hypoechoic lesions in spleen
Adapted from [8,41,52,57,60,82,84–87].
SIADH, syndrome of inappropriate anti-diuretic hormone secretion
Sa´nchez-Vargas and Go´mez-Duarte Mycoplasma pneumoniae 109
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 105–115
neurological complications remains unknown
because of the absence of an appropriate diag-
nostic test.
M. pneumoniae is a major cause of encephalitis
in children. Children aged <10 years are affected
more frequently than adults. Severe presentations
require intensive care management in up to 30%
of cases with CNS involvement. Long-term neu-
rological sequelae are documented in about
one-third of serologically confirmed cases of
encephalitis [61]. A prospective 5-year study of
children with acute encephalitis found evidence
of M. pneumoniae infection in 31% of all cases,
with M. pneumoniae being the probable cause of
encephalitis in 6.9% of cases, based on PCR
detection ofMycoplasma DNA in CSF and positive
serological results. Respiratory symptoms were
absent in 36% of patients with probable
M. pneumoniae encephalitis [62].
Acute transverse myelitis and acute dissemi-
nated encephalomyelitis are among the most
severe CNS manifestations of M. pneumoniae
infections. CNS symptoms and signs associated
with M. pneumoniae infections usually resolve
completely; however, a persistent neurological
deficit has been described in up to one-third of
patients [41,60].
The pathogenesis of CNS disease associated
with M. pneumoniae remains unknown, and
further research is underway to elucidate the
possible mechanism(s) of pathogenesis. Direct
invasion of the CNS by M. pneumoniae has been
implicated in early-onset encephalitis, but the
only evidence for this has been PCR-based detec-
tion of M. pneumoniae in CSF [52,53,63]. While
detection ofM. pneumoniae in the CNS may be the
result of migration of antigen-presenting cells
from pulmonary sites carrying Mycoplasma DNA
[64], it is known that M. hominis actively crosses
the blood–brain barrier to cause brain abscesses
[65]. Neurotoxin may also be implicated in the
pathogenesis of CNS disease, and an M. pneumo-
niae virulence factor with ADP-ribosyltransferase
activity and homology to pertussis toxin has been
described that leads to epithelial cell damage
in vitro [34]. This toxin may have systemic effects
that include the CNS. More studies are necessary
to elucidate the role of this toxin in Mycoplasma
extra-pulmonary disease. Immune response-med-
iated damage, by bacteria-induced immunosup-
pression, immune complexes or autoimmune
mechanisms, may better explain late-onset
encephalitis. Molecular mimicry and the produc-
tion of anti-human antibodies have been associ-
ated with Mycoplasma infections and antibodies
against brain tissue antigens that may contribute
to the neurological injury [66]. Lastly, thrombosis
and a hyper-coagulable state may lead to intra-
vascular coagulation and thromboembolic CNS
complications in association with Mycoplasma
[41,52].
The peripheral nervous system may also
be involved during M. pneumoniae infection in
children [67] and young adults. Studies in
individuals aged <35 years with Guillain–Barre´
syndrome have revealed a significant association
with M. pneumoniae infection [68].
DIAGNOSIS
M. pneumoniae infections cannot be diagnosed by
clinical findings alone, especially when they
present with extra-pulmonary symptoms. Before
the availability of new technologies, cold agglu-
tinins were used to confirm a diagnosis of
M. pneumoniae infection. Cold agglutinins are
IgM antibodies directed to antigen 1 on erythro-
cytes. They are produced 1 or 2 weeks after
infection in 50% of patients and may persist for
several weeks. Lack of sensitivity and specificity
render cold agglutinins irrelevant for diagnosis,
as they may also be present in infections caused
by viruses and other bacteria [52,69,70]. While
culture is considered to be the reference standard
for diagnosis, it is expensive and time-consuming,
and requires specialised media and technical
expertise. Furthermore, culture is not available
except in reference laboratories or large medical
centres (Table 4). Diagnosis of M. pneumoniae
infection is usually performed by serological
methods, such as passive agglutination, comple-
ment fixation and ELISA. A combination of PCR
and serology is recommended for reliable diag-
nosis [71]. Serological tests for anti-Mycoplasma
antibody represent the most common method for
retrospective diagnosis of Mycoplasma infections.
Evidence of seroconversion by collection of acute
and convalescent sera is the optimal method for
retrospective Mycoplasma diagnosis. Seroconver-
sion is defined as a four-fold increase in titre
between acute and convalescent sera, or a single
high anti-Mycoplasma complement fixation anti-
body titre of >1:128. False-positive results caused
by cross-reactions between antigens can occur.
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Serological testing is often hampered by inter-
species cross-reactions and even non-specific
reactions [41,72]. The sensitivity and specificity
of passive agglutination with single serum sam-
ples varies with the titre cut-off value used. It is
suggested that a titre of 1:80 or 1:160 is useful for
the diagnosis of M. pneumoniae infection in chil-
dren. Passive agglutination serology using paired
sera shows good agreement with PCR results [71].
ELISA is more sensitive than culture for detecting
acute infection, has sensitivity comparable to PCR
[71], but may be less sensitive than passive
agglutination [71]. Complement fixation tests,
indirect immunofluorescent assays and particle
agglutination assays have low sensitivity and
specificity [52].
PCR has been recommended for more sensitive
detection of M. pneumoniae, especially for patients
with neurological and other extra-pulmonary
manifestations [41]. PCR uses the same specimens
as does culture, but may also detectMycoplasma in
tissue processed for histological examination. The
advantages of PCR include high sensitivity and
specificity, rapid results, and no requirement for
viable microorganisms [8]. However, PCR assays
may overestimate the incidence of Mycoplasma
infections and, at present, there is no standardised
diagnostic method [72,73].
TREATMENT
While there is no disagreement concerning the
optimum antibiotic management of M. pneumo-
niae respiratory tract infections, controversy and
limited clinical evidence characterises the current
situation concerning management of non-pulmo-
nary conditions associated with M. pneumoniae.
Antibiotic management of Mycoplasma
respiratory infections
The absence of a cell wall renders these organisms
insensitive to b-lactam antibiotics. However, anti-
biotics acting at the level of protein synthesis or
DNA modification molecules are highly effective.
Macrolides, tetracyclines and fluoroquinolones
eliminate Mycoplasma efficiently both in vivo and
in vitro. Macrolides are the antibiotics of choice
for treating M. pneumoniae infections in both
adults and children. New macrolides are better-
tolerated, require fewer doses and have a shorter
treatment duration than older compounds.
In the ambulatory setting, it is more practical to
provide therapy empirically. However, if the
infection requires hospitalisation and the patient
has risk-factors, e.g., an underlying condition, or
an unfavourable prognosis, diagnostic testing is
recommended [74]. Use of tetracycline and fluor-
oquinolones is limited to adult patients or to
patients with an allergy to macrolides. Tetracy-
clines should not be used in children aged
<8 years. Azithromycin is given at recommended
doses for 5 days. Other macrolides such as clar-
ithromycin and erythromycin, as well as tetracy-
clines and fluoroquinolones, usually require
longer courses. A potential problem in the anti-
microbial management of M. pneumoniae infec-
tions is the emergence of macrolide resistance,
reported initially in Japan during 2000 [75].
Treatment of children with fluoroquinolones
may be possible; however, these agents are not
yet approved for use in children by the Federal
Drug Administration [76]. While M. pneumoniae
infections in the upper respiratory tract may
improve following antibiotic treatment, this is
not generally recommended, as such infections
are usually self-limiting. Some clinicians recom-
mend treatment of acute tonsillo-pharyingitis to
prevent the risk of recurrence of respiratory
illness [77].
Management of non-respiratory conditions
associated with Mycoplasma infections
Controversies in the management of non-respira-
tory conditions associated with M. pneumoniae
infections result from the limited knowledge of
Table 4. Diagnostic methods for Mycoplasma pneumoniae
Method Features
Culture Reference standard method
Not used routinely in clinical practice
Sensitivity no more than 60%
Specificity 100%
Disadvantages: laborious, expensive, long incubation periods
PCR Amplification of specific Mycoplasma DNA fragments
Advantages: may process histological samples, fluid, serum
Report available faster than serology
Does not require viable bacteria
Disadvantages: unable to distinguish colonisation from infection
Serology Advantages: easy to collect and to transport samples
Sensitivity 90%
Specificity 88% with titres >32 indicative of recent infection
Disadvantages: time-consuming, cross-reactions with other
Mycoplasma spp.
Other Antigen detection by immunofluorescence, agglutination,
immunoblotting
Low sensitivity and high cross-reactivity
Adapted from [41,70–73,87].
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their pathogenesis. While some extra-pulmonary
conditions may be caused by a post-inflammatory
response to M. pneumoniae infection, other condi-
tions may result from direct tissue damage caused
by this organism. Steroids have been used in
selected patients with severe CNS syndromes,
based on the presumed role of cytokines in
inflammation, despite the absence of any objective
prospective evaluation in clinical trials [41,52,63].
Case reports suggest that high-dose steroid ther-
apy may reverse neurological manifestations in
children. Aggressive therapy with steroids and
high-dosage immunoglobulins in children was
reported to improve outcome in cases of stroke
related to M. pneumoniae infection [53]. Even
severe cases of M. pneumoniae pneumonia in
children also benefit from the use of steroids in
conjunction with antibiotics [43].
In addition to steroids, other therapies, includ-
ing plasmapheresis, plasma exchange and intra-
venous IgG, have been used to treat patients with
severe CNS complications. None of these strate-
gies has been tested in randomised double-blind
clinical trials, and their benefit therefore remains
unclear. Plasmapheresis was reported to be effec-
tive in cases of transverse myelitis or polyradic-
ulitis [60]. Despite the absence of evidence, it
seems reasonable to consider the use of immuno-
modulatory therapies, together with antibiotics, in
severe cases.
The use of antibiotics for treating CNS
conditions associated with M. pneumoniae infec-
tion is also reported to have variable results.
Treatment with macrolides, tetracyclines, fluoro-
quinolones and chloramphenicol is limited to
case reports involoving severe CNS conditions
associated with Mycoplasma infections [78], and
an actual benefit from antibiotic therapy was
not demonstrated in most of the cases. The
rationale for antibiotic use is based on the PCR-
based detection of Mycoplasma DNA in CSF, and
the assumption that this DNA is evidence of
viable M. pneumoniae cells growing in the CNS.
However, microbiological studies have failed to
obtain positive M. pneumoniae cultures from
CSF, which suggests that other mechanisms of
pathogenesis may be involved.
Until more information is available concerning
the pathogenesis of M. pneumoniae-associated
extra-pulmonary conditions, it seems that sup-
portive treatment remains the most important
management approach [45], with the use of
steroids and antibiotics being considered on an
individual basis.
CONCLUSIONS
Mycoplasmas are fastidious microorganisms that
were first identified a century ago and have
subsequently been studied extensively both
in vivo and in vitro. Advances in laboratory
technology have significantly improved the
diagnosis of M. pneumoniae respiratory infections
and have increased the number of previously
unrecognised extra-pulmonary conditions associ-
ated with M. pneumoniae infection. However,
many questions remain unanswered concerning
pathogenesis, the role of host factors in clinical
presentation, and the medical management of
extra-pulmonary conditions. While clinical and
experimental evidence has accumulated concern-
ing the role of M. pneumoniae in activating pro-
inflammatory molecules and tissue inflammation,
little is known with respect to the effect of newly
described M. pneumoniae virulence factors on
direct tissue damage or systemic cytotoxicity.
Management of extra-pulmonary conditions is
controversial, as neither antibiotics nor anti-
inflammatory drugs have a clearly demonstrated
clinical benefit. Basic research on the molecular
biology of Mycoplasma infection will be important
in gaining an understanding of the pathogenesis
of the diverse clinical conditions associated with
these organisms. Furthermore, clinical studies on
the epidemiology and clinical management of
extra-pulmonary conditions will be essential to
better identify patients with conditions that may
benefit from antibiotic therapy and those that may
benefit from immunomodulatory therapies.
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